Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Sees Large Growth in Short Interest

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 115,672 shares, an increase of 32.9% from the December 15th total of 87,064 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily volume of 217,009 shares, the short-interest ratio is presently 0.5 days. Based on an average daily volume of 217,009 shares, the short-interest ratio is presently 0.5 days. Approximately 0.1% of the shares of the company are short sold.

Inventiva Stock Performance

Shares of IVA stock traded up $0.39 during trading hours on Monday, reaching $6.51. 387,465 shares of the company’s stock were exchanged, compared to its average volume of 386,740. The company’s 50 day moving average is $4.51 and its two-hundred day moving average is $4.58. Inventiva has a 1 year low of $2.11 and a 1 year high of $7.98.

Institutional Trading of Inventiva

Several large investors have recently bought and sold shares of IVA. NewEdge Advisors LLC acquired a new stake in Inventiva in the 3rd quarter valued at about $116,000. Millennium Management LLC purchased a new position in Inventiva in the 3rd quarter valued at about $649,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Inventiva by 55.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after purchasing an additional 9,212 shares during the last quarter. Finally, Creative Planning purchased a new stake in shares of Inventiva during the second quarter worth about $32,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Analyst Ratings Changes

IVA has been the subject of a number of recent analyst reports. Leerink Partnrs raised shares of Inventiva to a “strong-buy” rating in a report on Monday, January 12th. Wall Street Zen raised shares of Inventiva to a “hold” rating in a report on Saturday, October 18th. Leerink Partners initiated coverage on Inventiva in a report on Monday, January 12th. They set an “outperform” rating and a $12.00 price target for the company. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. Finally, UBS Group assumed coverage on shares of Inventiva in a report on Wednesday, January 7th. They set a “buy” rating and a $12.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $16.00.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.